AGIO
Price
$27.44
Change
-$0.85 (-3.00%)
Updated
Jun 8, 04:59 PM (EDT)
Capitalization
1.63B
52 days until earnings call
Intraday BUY SELL Signals
BEAM
Price
$29.78
Change
+$0.38 (+1.29%)
Updated
Jun 8, 04:59 PM (EDT)
Capitalization
3.06B
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AGIO vs BEAM

Header iconAGIO vs BEAM Comparison
Open Charts AGIO vs BEAMBanner chart's image
AGIO vs BEAM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AGIO vs. BEAM commentary
Jun 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a StrongBuy and BEAM is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2026
Stock price -- (AGIO: $27.44 vs. BEAM: $29.78)
Brand notoriety: AGIO and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 49% vs. BEAM: 63%
Market capitalization -- AGIO: $1.63B vs. BEAM: $3.06B
AGIO [@Biotechnology] is valued at $1.63B. BEAM’s [@Biotechnology] market capitalization is $3.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $112.43B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).

  • AGIO’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than AGIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 5 bullish TA indicator(s).

  • AGIO’s TA Score: 4 bullish, 4 bearish.
  • BEAM’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than AGIO.

Price Growth

AGIO (@Biotechnology) experienced а -2.00% price change this week, while BEAM (@Biotechnology) price change was -4.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.10%. For the same industry, the average monthly price growth was -7.08%, and the average quarterly price growth was -4.86%.

Reported Earning Dates

AGIO is expected to report earnings on Jul 30, 2026.

BEAM is expected to report earnings on Aug 11, 2026.

Industries' Descriptions

@Biotechnology (-7.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($3.06B) has a higher market cap than AGIO($1.63B). BEAM YTD gains are higher at: 7.431 vs. AGIO (0.808). BEAM has higher annual earnings (EBITDA): -349.25M vs. AGIO (-470.27M). BEAM has more cash in the bank: 1.21B vs. AGIO (114M). AGIO has less debt than BEAM: AGIO (35.7M) vs BEAM (251M). BEAM has higher revenues than AGIO: BEAM (164M) vs AGIO (66M).
AGIOBEAMAGIO / BEAM
Capitalization1.63B3.06B53%
EBITDA-470.27M-349.25M135%
Gain YTD0.8087.43111%
P/E Ratio3.82N/A-
Revenue66M164M40%
Total Cash114M1.21B9%
Total Debt35.7M251M14%
FUNDAMENTALS RATINGS
AGIO vs BEAM: Fundamental Ratings
AGIO
BEAM
OUTLOOK RATING
1..100
5019
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9793
PRICE GROWTH RATING
1..100
5345
P/E GROWTH RATING
1..100
52100
SEASONALITY SCORE
1..100
7590

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (28) in the null industry is in the same range as AGIO (47) in the Biotechnology industry. This means that BEAM’s stock grew similarly to AGIO’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as AGIO (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to AGIO’s over the last 12 months.

BEAM's SMR Rating (93) in the null industry is in the same range as AGIO (97) in the Biotechnology industry. This means that BEAM’s stock grew similarly to AGIO’s over the last 12 months.

BEAM's Price Growth Rating (45) in the null industry is in the same range as AGIO (53) in the Biotechnology industry. This means that BEAM’s stock grew similarly to AGIO’s over the last 12 months.

AGIO's P/E Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that AGIO’s stock grew somewhat faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOBEAM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
76%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
75%
Bullish Trend 5 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
76%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 1 day ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
AGIO
Daily Signal:
Gain/Loss:
BEAM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IGRO87.130.10
+0.12%
iShares International Dividend Gr ETF
LGI18.170.02
+0.11%
Lazard Global Total Return & Income Fund
JULM34.490.02
+0.06%
FT Vest U.S. Eq Max Buffr ETF - Jul
APRZ39.49N/A
N/A
TrueShares Structured Outcome April ETF
VGUS75.50-0.01
-0.01%
Vanguard Ultra-Short Treasury ETF

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with TPST. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then TPST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
-3.00%
TPST - AGIO
48%
Loosely correlated
+0.79%
AXON - AGIO
45%
Loosely correlated
-3.10%
NRIX - AGIO
45%
Loosely correlated
+6.83%
VCYT - AGIO
38%
Loosely correlated
-2.96%
CNTN - AGIO
37%
Loosely correlated
+15.65%
More